/ Print /

PHARMACY BEST PRACTICES

Are payers optimistic about biosimilars’ savings?As more biosimilars are approved, plans and PBMs will continue to evolve their strategies regarding coverage and formulary management of these new medications.
Hodgkin lymphoma: First hematologic cancer cured with immunotherapy?Immune checkpoint inhibitors are taking the stage in treating relapsed and refractory Hodgkin lymphoma. Read more.
Four innovative models rein in pharma costs
Four innovative models rein in pharma costsPlans and PBMs are finding new ways to rein in pharmacy costs.
Integrating pharmacy benefit, medical benefit cuts costsHere’s how one non-profit health plan harnessed the power of medical and pharmacy data to rein in drug costs.
Aggressive price growth pushes healthcare spending upRise in use of outpatient care and professional services contributed to quicker growth in spending for the privately insured over previous years.
Four ways Medicare Part D has affected costs for diabetic patientsUnderstand Medicare Part D’s design and its coverage gap to offer the most affordable prescription drug options for patients.
Three data-driven practices that boost adherenceHere’s a three-pronged approach to improve adherence program efficiency that leverages predictive data analytics, hospital on-site pharmacies and post discharge follow-up evaluation to achieve real, measurable results.
Five things physicians don’t know about biosimilarsAwareness of biosimilars is high, but there are some gaps to be filled, according to a Biosimilars Forum study.
How state-mandated formularies impact costsResearch by Express Scripts presented at the AMCP examines costs among Medicaid members in the Florida plan to members in a similar Medicaid plan without a state-mandated formulary.
Four things health execs should know about the oncology pipeline
Four things health execs should know about the oncology pipelineHere’s how you can recognize changes in the oncology pipeline and maximize value related to cancer care.